• Treatment of non-muscle invasive bladder cancer
  • The EAU approach to non-muscle invasive bladder cancer treatment
  • A single chemotherapy dose for low- or intermediate-risk patients
  • Further chemotherapy or long-term BCG treatment for intermediate-risk patients
  • TURBT and then some
  • References
  • About Mitomycin-C Kyowa
  • Mechanism of Action
  • Solubility
  • Stability
  • Dosage, indication & side effects
  • Useful links
  1. Top >
  2. for Healthcare Professionals >
  3. The EAU approach to non-muscle invasive bladder cancer treatment

Treatment of non-muscle invasive bladder cancer

The EAU approach to non-muscle invasive bladder cancer treatment

The European Association of Urology regularly update their guidelines for the treatment of non-muscle invasive bladder cancer. These are based on the latest available clinical evidence.

Their latest guidelines (2013) recommend different treatments depending on how likely a patient’s cancer is to recur or progress.

Their main recommendations are:1

A single chemotherapy dose for low- or intermediate-risk patients

"One, immediate, post-operative intravesical instillation of chemotherapy."

Further chemotherapy or long-term BCG treatment for intermediate-risk patients

For patients with intermediate to high recurrence risk and intermediate progression risk "further instillations of chemotherapy or a minimum of one year of BCG."

Long-term BCG treatment or immediate cystectomy for high-risk patients

"Intravesical BCG for at least one year, or immediate cystectomy."

How do EAU guidelines influence your clinical decisions?

< Back A single chemotherapy dose for low- or intermediate-risk patients >